Minimize Uncertainty – Make Informed Decisions – Succeed

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Teva and Blackstone Life Sciences $400m duvakitug financing

March 5, 2026clinical trials,market access,immunology,Ulcerative Colitis,Crohns Disease,biopharma,Lucid Diligence Brief,diligence,inflammatory bowel disease,royalties,financing,payer strategySanofi partnership

Lucid Diligence Brief: Teva and Blackstone Life Sciences $400m duvakitug…

by Timos Papagatsias

Neuroscience

Neuroscience Video Recap—March 4, 2026

March 4, 2026Ionis Pharmaceuticals,Axsome Therapeutics,multiple sclerosis,IRLAB Therapeutics,Teva,Excessive daytime sleepiness,Alzheimer's Disease,Primary Central Nervous System Lymphoma,roche,Tirabrutinib,Huntington's disease,Down Syndrome,schizophrenia,Spinal muscular atrophy type 1,BioPharma and Tech News,Solriamfetol,Deciphera,Parkinson’s Disease Apathy,Ono Pharmaceutical,uniQure,Neuroscience News,MedinCellMajor depressive disorder,Fenebrutinib

This biweekly Neuroscience video recap highlights key regulatory filings, Phase…

by LucidQuest

Neuroscience

Neuroscience Today—March 4, 2026

March 4, 2026multiple sclerosis,gene therapy,novartis,roche,Huntington's disease,BioPharma and Tech News,Parkinson's Disease,BTK Inhibitor,Rett syndrome,Neuroscience NewsFenebrutinib,Spinal muscular atrophy type 1

This week's Neuroscience update covers key developments across late-stage…

by LucidQuest

Immunology

Immunology Today—March 4, 2026

March 4, 2026sanofi,BioPharma and Tech News,Crohns Disease,Alopecia Areata,Johnson & Johnson,Immunology News,Dupixent,FcRn inhibitors,JAK inhibitors,chronic spontaneous urticariawarm autoimmune hemolytic anemia,IL-23 inhibitors

This week's Immunology update covers key regulatory actions, clinical trial…

by LucidQuest

Women's_Health

Women’s Health Video Recap—March 4, 2026

March 4, 2026FimmCyte,Celmatix,roche,Women’s Health Coalition Of Canada,breast cancer,MediKarma,BioPharma and Tech News,Nanell,endometriosis,EncorVita Health,Oura,Eterna Inc.,giredestrant,Bristol Myers Squibb,Women's Health News,Triple-negative breast cancer,Gedeon Richter,SystImmune,Izalontamab BrengitecanFertility,Ovarian Ageing

This biweekly Women’s Health video recap highlights regulatory momentum in…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Poplar Therapeutics $95 million Series A

March 4, 2026clinical trials,biologics,FDA,immunology,biopharma,Lucid Diligence Brief,payer access,diligence,venture funding,allergyfood allergy

Lucid Diligence Brief: Poplar Therapeutics $95 million Series A extension…

by Timos Papagatsias

Obesity Weekly News

Obesity Video Recap—March 3, 2026

March 3, 2026United Bio-Technology,Rhythm Pharmaceuticals,semaglutide,Acquired Hypothalamic Obesity,BioPharma and Tech News,Bloom Science,obesity,Pfizer China,Novo Nordisk,Hangzhou Sciwind Biosciences,Zepbound,Vivtex Corporation,Orforglipron,Daewoong Therapeutics,Setmelanotide,Obesity News,Ecnoglutide,Daewoong Pharmaceutical,Taltz,Eli Lilly And CompanyPeptron,United Laboratories

This biweekly Obesity video recap highlights late-stage combination data,…

by LucidQuest

Endocrinology

Endocrinology Today—March 3, 2026

March 3, 2026BioPharma and Tech News,Novo NordiskT2D,thyroid cancer,Eli Lilly,type 2 diabetes,type 1 diabetes,Orforglipron,GLP-1 receptor agonist,Endocrinology News,Central diabetes insipidus,Desmopressin

This week’s Endocrinology update highlights regulatory approvals, Phase 3…

by LucidQuest

Obesity Weekly News

Obesity Today—March 3, 2026

March 3, 2026Phase 1b clinical trials,Ketogenic biology therapeutics,BioPharma and Tech News,Diabetes and obesity drug development,GLP-1 Receptor Agonists,Obesity News,Obesity treatment innovation,Triple agonist therapies,Oral biologics delivery technology,Microneedle drug delivery patches,Live biotherapeutic products,Metabolic health clinics,Real-world clinical outcomes,MC4R pathway therapies,Hypothalamic obesity treatmentWegovy biosimilars,China biotech partnerships

This week’s Obesity update highlights real-world care-model outcomes,…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and Tedopi

March 3, 2026immunology,NSCLC,Ulcerative Colitis,biopharma,hidradenitis suppurativa,immuno-oncology,Lucid Diligence Brief,diligence,partnering,catalysts,pouchitistherapeutic vaccines

Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and…

by Timos Papagatsias

Oncology News

Oncology Video Recap—March 2, 2026

March 2, 2026Ficlatuzumab,Siren Biotechnology,astrazeneca,Recurrent High-Grade Glioma,pfizer,Alpha Tau Medical,roche,Alpha DaRT,breast cancer,Unresectable Head And Neck Cancer,BioPharma and Tech News,ENHERTU,Johnson & Johnson,Daiichi Sankyo,giredestrant,Oncology News,metastatic colorectal cancer,Rybrevant FASPROBRAFTOVI,AVEO Oncology

This biweekly Oncology and Biopharma Regulatory Watch video recap highlights…

by LucidQuest

Onco_background

Oncology Today—March 2, 2026

March 2, 2026pfizer,BioPharma and Tech News,Enzalutamide,Johnson & Johnson,Oncology News,Non-small cell lung cancer,metastatic colorectal cancer,Rybrevant,BRAFTOVI,Metastatic castration-resistant prostate cancerPediatric low-grade glioma,Radium-223

This week’s Oncology update highlights major regulatory approvals,…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.